Core Viewpoint - Venus Concept Inc. has announced its decision to voluntarily delist its common stock from the NASDAQ Capital Market and deregister its common stock with the SEC, citing that the costs of compliance outweigh the benefits for the company and its shareholders [1][2]. Delisting and Deregistration - The company is compliant with Nasdaq listing requirements but has determined that the resources needed for SEC reporting obligations are excessive compared to the benefits [2]. - Venus Concept has notified Nasdaq of its intent to delist and deregister, planning to file a Form 25 on or about January 30, 2026, with the last trading day expected to be around February 6, 2026 [3]. - A Form 15 will be filed on or about February 9, 2026, which will suspend the company's obligation to file periodic reports with the SEC [3]. Management's Perspective - The Board of Directors believes that this decision is in the best interests of the company and its shareholders, as it will reduce compliance costs and support the execution of the company's turnaround plan [4]. - The CEO of Venus Concept emphasized the collaboration with Madryn Asset Management to position the company for long-term financial success [4]. Company Overview - Venus Concept is a global leader in medical aesthetic technology, offering a wide range of minimally invasive and non-invasive products, reaching over 60 countries [5]. - The product portfolio includes various aesthetic device platforms and hair restoration systems, supported by prominent healthcare industry investors [5].

Core Insights - Venus Concept (VERO) shares surged nearly 460% on January 16 after Madryn Asset Management revealed a 91% ownership stake in the company [1] - Following the initial surge, VERO shares reversed gains, trading at approximately $4.20 compared to a high of around $13 [2] - The lack of fundamental operational improvements raises concerns about whether the price rally is based on genuine value or speculative momentum [3] Group 1 - The announcement of Madryn's ownership stake coincided with discussions on cost reduction strategies, including potential delisting and deregistration of the stock [1] - The extraordinary gains in VERO shares have led to immediate weakness, indicating unfavorable risk-reward dynamics for investors considering chasing the rally [4] - Historical data shows that Venus has averaged a decline of over 4% in February over the past eight years, making the stock less attractive in the near term [6] Group 2 - The absence of Wall Street coverage for Venus Concept is a significant concern, as it leaves investors without professional guidance on valuation and future prospects [7] - The potential for delisting signals a reduction in market accessibility and liquidity, further complicating the investment landscape for VERO shares [5] - Historical patterns suggest that chasing such significant rallies often results in suboptimal risk-adjusted returns, as profit-taking can lead to substantial retracement [5]

Core Insights - Three stocks in the health care sector are signaling potential warnings for momentum-focused investors as of January 20, 2026 [1] Group 1: Overbought Stocks - Venus Concept Inc (NASDAQ:VERO) has an RSI value of 95.9, with shares gaining 451.8% to close at $7.89 on Friday, and a 52-week high of $14.50 [2][5] - ImmunityBio Inc (NASDAQ:IBRX) has an RSI value of 95.4, with shares rising 39.8% to close at $5.52 on Friday, and a year-to-date increase of over 100% [2][5]

Core Viewpoint - Venus Concept Inc. (NASDAQ:VERO) experienced a significant stock price increase of over 500% on Friday, driven by high trading volume and strategic investment developments [1]. Group 1: Stock Performance - Venus Concept stock surged 593.01% to $9.91 at publication, with a trading volume of 223.09 million shares compared to an average volume of 1.74 million [1][6]. Group 2: Major Stake Acquisition - Madryn Asset Management disclosed a 91% stake in Venus Concept, indicating the investment is for strategic purposes [2]. - As a major shareholder, Madryn Asset Management plans to engage actively in operational, financial, and strategic initiatives, including evaluating potential strategic alternatives for the company [3]. Group 3: Financial Performance - Venus Concept reported third-quarter sales of $13.78 million, which fell short of the consensus estimate of $14.48 million, marking an 8% year-over-year decline and a 12% quarter-over-quarter decline, primarily due to a downturn in the Hair Restoration business [4]. Group 4: Product Development - The U.S. FDA granted 510(k) clearance to Venus Concept's Venus NOVA, a next-generation multi-application platform aimed at enhancing non-invasive treatments for various aesthetic applications [5]. - Venus NOVA features Adaptive Electrical Muscle Stimulation (EMS), Multi-Polar Radio Frequency (RF), Pulsed Electromagnetic Fields (PEMF), and Advanced VariPulse technology, providing a comprehensive solution for body contouring and skin treatments [6].

Core Insights - Venus Concept Inc. has received FDA 510(k) clearance for its new product, Venus NOVA, marking a significant milestone in the company's R&D strategy [1][3] - Venus NOVA is designed to provide a comprehensive solution for non-invasive body, face, and skin treatments, integrating multiple advanced technologies [2][3] Product Features - Venus NOVA incorporates Adaptive Electrical Muscle Stimulation (EMS), Multi-Polar Radio Frequency (RF) combined with Pulsed Electromagnetic Fields (PEMF), and Advanced VariPulse™ technology [2][4] - The platform aims to enhance body contouring, muscle conditioning, skin treatments, and reduce wrinkles and cellulite [2] Strategic Initiatives - The launch of Venus NOVA aligns with the company's turnaround strategy initiated in 2023 and the Venus AI strategic initiative, focusing on innovation and customer partnerships [3] - The product is expected to support the growing demand for aesthetic treatments, particularly for patients using GLP-1 medications, with an anticipated increase to over 32 million users globally by 2030 [3] Market Positioning - Venus NOVA is positioned to penetrate the multi-billion-dollar body and skin market, contributing to the company's long-term growth profile [3] - The product will be available in the U.S. starting December 2025, with global rollouts planned for 2026 and beyond [6] Support Programs - The Venus Jumpstart Program will provide a 30-day roadmap for advanced clinical education and marketing enablement to ensure successful integration of Venus NOVA into existing practices [4][5]

Core Viewpoint - Venus Concept Inc. has successfully reduced its outstanding debt by exchanging $11.48 million of subordinated convertible notes for preferred stock, improving its financial position significantly [1][2]. Financial Position - The total debt obligations of Venus Concept are now approximately $30.1 million, reflecting a 24% reduction from $39.7 million as of December 31, 2024 [1]. Strategic Initiatives - The debt-to-equity exchange is part of Venus Concept's strategy to enhance financial flexibility and support long-term growth and profitability [2]. - The partnership with Madryn Asset Management is viewed as invaluable in advancing the company's transformation plan [2]. Company Overview - Venus Concept is a global leader in medical aesthetic technology, offering a wide range of minimally invasive and non-invasive products across over 60 countries [4]. - The product portfolio includes various aesthetic device platforms and hair restoration systems, supported by prominent healthcare industry investors [4].

Core Points - Venus Concept Inc. will release its third quarter financial results for fiscal year 2025 on November 13, 2025, before market opening [1] - A conference call will be held at 8:00 a.m. Eastern Time on the same day to discuss the results and answer questions [2] - A replay of the conference call will be available for two weeks for those unable to participate live [3] Company Overview - Venus Concept is a global leader in medical aesthetic technology, offering a wide range of minimally invasive and non-invasive products [4] - The company operates in over 60 countries and has 9 direct markets, with a diverse product portfolio including various aesthetic device platforms and hair restoration systems [4] - Venus Concept is supported by prominent healthcare industry growth equity investors [4]

Company Overview - Venus Concept Inc. is a global leader in medical aesthetic technology, offering a wide range of minimally invasive and non-invasive products for aesthetic and hair restoration [4] - The company operates in over 60 countries and has 9 direct markets, showcasing its extensive reach in the industry [4] - Venus Concept's product portfolio includes various aesthetic device platforms and hair restoration systems, such as NeoGraft® and the ARTAS iX® Robotic Hair Restoration system [4] Financial Results Announcement - The company will release its second quarter fiscal year 2025 financial results after market close on August 14, 2025 [1] - A conference call will be held at 5:00 p.m. Eastern Time on the same day to discuss the results and answer questions [2] - For those unable to attend, a replay of the call will be available for two weeks, and a webcast will be archived on the company's investor relations website [3] Investor Relations - Investor relations contact for Venus Concept is managed by ICR Healthcare, with Mike Piccinino, CFA, as the point of contact [5]

Core Insights - Venus Concept Inc. has successfully exchanged $6.5 million of subordinated convertible notes for 325,651 shares of Series Y preferred stock, resulting in a 14% reduction in total debt obligations from $39.7 million to approximately $34.3 million [1][2] Group 1: Financial Position - The debt exchange improves the Company's balance sheet and provides financial flexibility for ongoing strategic initiatives, including the divestiture of the Venus Hair business [2] - The total debt reduction reflects the Company's commitment to optimizing its capital structure [2] Group 2: Management Commentary - The CEO of Venus Concept emphasized the importance of the partnership with Madryn Asset Management in achieving financial flexibility and supporting the Company's transformation plan [2] - Madryn Asset Management expressed support for the management team and the Company's efforts to return to growth [2] Group 3: Company Overview - Venus Concept is a global leader in medical aesthetic technology, offering a wide range of minimally invasive and non-invasive products across over 60 countries [4] - The product portfolio includes various aesthetic device platforms and hair restoration systems, backed by prominent healthcare industry investors [4]

Core Viewpoint - Venus Concept Inc. has successfully closed a registered direct offering, raising approximately $1.15 million, with potential additional proceeds of up to $2.3 million from unregistered short-term warrants [1][3]. Group 1: Offering Details - The company sold 434,720 shares of common stock at a price of $2.65 per share [1]. - Concurrently, unregistered short-term warrants were issued to purchase up to 869,440 shares at the same exercise price, which are immediately exercisable and will expire in eighteen months [1][3]. - The gross proceeds from the offering are approximately $1.15 million before fees and expenses [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be used for general corporate purposes [3]. Group 3: Company Overview - Venus Concept is a global leader in medical aesthetic technology, offering a wide range of minimally invasive and non-invasive products across over 60 countries [7]. - The product portfolio includes various aesthetic device platforms and hair restoration systems, supported by prominent healthcare growth equity investors [7].